Cargando…
Basaglar: A Hypersensitivity Reaction
Autores principales: | Gavioli, Elizabeth M., Fazylov, Roman, Sardo, Gulmira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898161/ https://www.ncbi.nlm.nih.gov/pubmed/29686464 http://dx.doi.org/10.2337/cd17-0051 |
Ejemplares similares
-
Basaglar
por: Newsome, Cheyenne
Publicado: (2017) -
Real-World Impact of Switching From Insulin Glargine (Lantus(®)) to Basaglar(®) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2022) -
Similar Efficacy and Safety of Basaglar(®) and Lantus(®) in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study
por: Pollom, Robyn K., et al.
Publicado: (2018) -
Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015) -
Carboplatin-Induced Hypersensitivity Reaction
por: Potolidis, Evangelos, et al.
Publicado: (2012)